CDC42 and ovarian cancer: R-naproxen demonstrated the same activities against Rho-family GTPases Rac1 and Cdc42 as R-ketorolac in immortalized ovarian cancer (OvCa429, OvCa433) and cervical cancer (HeLa T4+) cells.